Sign up for the biotech newsletter to stay informed about the latest developments in science and politics driving the biotech industry. This morning, Novo Nordisk’s CagriSema results disappointed investors, leading to a significant drop in their stock value. Ionis Pharmaceuticals received FDA approval for their rare disease therapy, marking a strategic shift towards independent commercialization. The FDA also announced the end of the tirzepatide shortage. Additionally, there is a discussion on the need for more transparency in gene therapy studies and the challenges faced by patients in accessing certain medications. Listen to the latest episode of “The Readout LOUD” for more insights on biotech industry updates.
Source link
Makary, Ionis, CagriSema news updates
